Table 3 Index and post-index nAMSM treatment patterns, overall and by prior mAb use

Index medication and dose, n (%)

 Rimegepant

27,140 (34.5%)

8,465 (31.8%)

18,675 (36.0%)

  Rimegepant 75mg

27,140 (100.0%)

8,465 (100.0%)

18,675 (100.0%)

 Ubrogepant

49,187 (62.6%)

17,084 (64.1%)

32,103 (61.8%)

  Ubrogepant 50mg

33,065 (67.2%)

10,961 (64.2%)

22,104 (68.9%)

  Ubrogepant 100mg

16,101 (32.7%)

6,115 (35.8%)

9,986 (31.1%)

 Lasmiditan

2,247 (2.9%)

1,107 (4.2%)

1,140 (2.2%)

  Lasmiditan 50mg

731 (32.5%)

319 (28.8%)

412 (36.1%)

  Lasmiditan 100mg

1,513 (67.3%)

788 (71.2%)

725 (63.6%)

Index nAMSM quantity dispensed

 Mean (SD) [median]

9.98 (4.28) [10]

9.97 (4.13) [10]

9.98 (4.35) [10]

Number of refills^b for index medication, n (%)

 0 refills

27,136 (34.5%)

7,698 (28.9%)

19,438 (37.4%)

 1 refill

15,152 (19.3%)

4,996 (18.7%)

10,156 (19.6%)

 2 refills

11,110 (14.1%)

3,846 (14.4%)

7,264 (14.0%)

 3 refills

8,378 (10.7%)

3,141 (11.8%)

5,237 (10.1%)

 4 + refills

16,798 (21.4%)

6,975 (26.2%)

9,823 (18.9%)

Refills^b for index therapy among patients with ≥ 1 refill

 Patients with ≥ 1 refill, n (%)

51,438 (65.5%)

18,958 (71.1%)

32,480 (62.6%)

 Number of refills, mean (SD) [median]

2.91 (1.94) [2]

3.11 (2.03) [3]

2.80 (1.88) [2]

 Days from index date to first refill, mean (SD) [median]

53.3 (38.3) [39]

50.3 (36.6) [37]

55.0 (39.2) [41]

Switch from index nAMSM to a different nAMSM

 Patients with ≥ 1 nAMSM switch

8,122 (10.3%)

4,091 (15.4%)

4,031 (7.8%)